Navigation Links
PEAK Surgical Announces Positive Surgical Incision Wound Healing Results With the PEAK PlasmaBlade(TM)
Date:10/9/2007

el and electrosurgery approaches -- enabling surgeons to cut soft tissue precisely with little damage to surrounding tissues and to control bleeding. Preclinical studies have shown that this may provide significant benefits for both surgeons and patients, including increased procedure efficiency, lower infection rates, faster recovery, reduced scarring and stronger wound healing.

PEAK's technology was successfully evaluated by Stanford University researchers in ophthalmology trials, including in retinal and cataract surgery. Results of the clinical use of PEAK's technology have been published in several peer-reviewed journals, including Retina, Archives of Ophthalmology, Journal of Cataract & Refractive Surgery and the British Journal of Ophthalmology.

The PULSAR Surgery System is not yet available in the United States. The Company is in the process of filing pre-market notification with the U.S. Food and Drug Administration and is planning to conduct additional preclinical studies of the technology.

About PEAK Surgical

PEAK Surgical is a medical device company developing a next-generation tissue dissection system with distinct advantages over surgical instruments in standard use today. The Company is exploring applications of its PEAK(TM) Pulsed Plasma Technology in numerous surgical fields. For more information, please visit http://www.peaksurgical.com.

Abstract number SF2007-458. "Comparative Healing of Surgical Incisions Created by a Standard "Bovie," PEAK(TM) PlasmaBlade and Standard Scalpel Blade." Presented at the American College of Surgeons 93rd Annual Clinical Congress on Tuesday, October 9, 2007, in New Orleans.


'/>"/>
SOURCE PEAK Surgical, Inc.
Copyright©2007 PR Newswire.
All rights reserved

2

GOOD

Page: 1 2 3

Related medicine news :

1. Indonesian boy with huge neck tumor was surgically removed
2. New spray gel heals surgical wounds
3. FDA approves surgical gel
4. Lower surgical volume linked to higher death rate
5. Sleep apnoea linked to surgical risks
6. Treatment Of Brain Aneurysms By A New Non-Surgical Approach
7. Complete Robotic Surgery To Revolutionize Surgical Treatment of Prostate Cancer
8. Surgeon Attempts to Create A Surgical Hernia Feat
9. Researchers Aim To Develop Next Generation Of Surgical Robots
10. Arrow Embedded In Tribal’s Chest For Two Weeks Surgically Remove
11. Surgical Intervention to Solve Obesity and Related Problems
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/8/2009)...ONTO, Jan. 8 /PRNewswire-FirstCall/ - Med-Emerg In... Canada,s leading providers of health services, is...ted in favour of the previously announced plan of ...oup Inc. ("AIM") at a special meeting of MedEmerg,... 90% of the votes cast at the meeting were in favo...
(Date:1/8/2009)...XANDRIA, Va., Jan. 8 To...nization along with several national leadership or... the principles of hospice care and protection of ...anding together in sharing this unified message ab...of Hospice and Palliative Medicine, Hospice and Pa...
(Date:1/8/2009)...ifornia Assembly Member Tom Torlakson Introduces A...-USNewswire/ -- Today, Lung Cancer Alliance-Cali... Tom Torlakson (D-11th District) for his continued...unding for lung cancer research. For the third co...ancer research is being considered in the Californ...
(Date:1/8/2009)...says it lowered bad cholesterol more effectively t...y News) -- After nearly a year of review, U.S. hea...e continued use of the controversial cholesterol-l...Administration said there was no significant diffe... taking Vytorin and patients taking the drug Zocor...
Breaking Medicine News(10 mins):Health News:Shareholders of Med-Emerg International Inc. approve plan of arrangement with AIM Health Group Inc. 2Health News:National End-of-Life Organizations Release Consensus Statement on Hospice, the Medicare Hospice Benefit, and Key Issues for the Future 2Health News:National End-of-Life Organizations Release Consensus Statement on Hospice, the Medicare Hospice Benefit, and Key Issues for the Future 3Health News:National End-of-Life Organizations Release Consensus Statement on Hospice, the Medicare Hospice Benefit, and Key Issues for the Future 4Health News:National End-of-Life Organizations Release Consensus Statement on Hospice, the Medicare Hospice Benefit, and Key Issues for the Future 5Health News:National End-of-Life Organizations Release Consensus Statement on Hospice, the Medicare Hospice Benefit, and Key Issues for the Future 6Health News:National End-of-Life Organizations Release Consensus Statement on Hospice, the Medicare Hospice Benefit, and Key Issues for the Future 7Health News:Lung Cancer Alliance Applauds New Legislation Funding Lung Cancer Research 2Health News:FDA Backs Cholesterol Drug Vytorin 2
... walk and stick to healthy food. That is a far mor... a group of US scientists has said.// In fact pr...tified when lifestyle changes are just as effectiv...osiglitazone pills do work, but so does weight los...
...ch has shown a way for people suffering diabetic r...arding as well as alleviating the effects of diabe... consequence of diabetes. In the initial stages, ...le symptoms but is capable of progressing graduall...
... outcomes for blacks with cardiovascular disease a...ferences in access and treatment are minimized, ac...rt Journal, Reuters reports. For the study, Nanc...emorial Veterans Hospital and colleagues studied t...
...w of the massacre that took place last week at the...iversity officials are asking the congressmen to f...isaster. Some kind of program, to identify and tre... and the others. A law that would permit the unive...
Other Medicine News:Health News:Lifestyle changes not prescription drugs to fight diabetes, say scientists 2Health News:Measures Needed to Avert Another Bloodbath 2
(Date:1/8/2009)...ated at the initial dose in an ongoing Phase Ib tr...line after three days , , Conference Call Today...re-FirstCall/ -- Anadys Pharmaceuticals, Inc. (Nas...st cohort of an ongoing Phase Ib clinical trial of...ide polymerase inhibitor. ANA598 was very well-to...
(Date:1/7/2009)...n., Jan. 7 Scientists h...high likelihood of relapse in children with acute ...hers caution that further research is needed to de... IKAROS, lead to leukemia relapse, the findings ...tic tests to assess the risk of treatment failure....
(Date:1/7/2009)...d., Jan. 7 ImQuest Life Sciences a... application to the Food and Drug Administration t...rimidinedione HIV inhibitor IQP-0410. ImQuest anti...rst quarter of 2009. IQP-0410 is a novel small mol...onnucleoside reverse transcriptase inhibitor (NNRT...
(Date:1/7/2009).... 7 Tiantan Puhua Hospital Stem Ce...worldwide leader in using stem cells to effectivel...x new globally experienced additions to its medica... hospital,s treatment capabilities for growing num...enior doctors include the distinguished Dr. Jiang ...
Breaking Medicine Technology:ANA598 Demonstrates Potent Antiviral Activity in an Early Clinical Study in HCV-Infected Patients 2ANA598 Demonstrates Potent Antiviral Activity in an Early Clinical Study in HCV-Infected Patients 3ANA598 Demonstrates Potent Antiviral Activity in an Early Clinical Study in HCV-Infected Patients 4ANA598 Demonstrates Potent Antiviral Activity in an Early Clinical Study in HCV-Infected Patients 5ANA598 Demonstrates Potent Antiviral Activity in an Early Clinical Study in HCV-Infected Patients 6Gene Abnormality Found to Predict Childhood Leukemia Relapse 2Gene Abnormality Found to Predict Childhood Leukemia Relapse 3Gene Abnormality Found to Predict Childhood Leukemia Relapse 4Gene Abnormality Found to Predict Childhood Leukemia Relapse 5Gene Abnormality Found to Predict Childhood Leukemia Relapse 6ImQuest Submits Investigational New Product Application to the Food and Drug Administration to Initiate HIV Therapeutic Clinical Trials with IQP-0410 2Stem Cell Treatment Leader Tiantan Puhua Adds Experienced International Medical Staff for Expanding Numbers of Patients 2Stem Cell Treatment Leader Tiantan Puhua Adds Experienced International Medical Staff for Expanding Numbers of Patients 3Continuous Blood Pressure Monitoring Predicts Risks 30515 1Continuous Blood Pressure Monitoring Predicts Risks 30515 2Continuous Blood Pressure Monitoring Predicts Risks 30515 311 4 25 Shareholders 26 Former Executive Management of LCA Vision Express Shock and Disbelief at Recent Adoption of Poison Pill 30512 111 4 25 Shareholders 26 Former Executive Management of LCA Vision Express Shock and Disbelief at Recent Adoption of Poison Pill 30512 211 4 25 Shareholders 26 Former Executive Management of LCA Vision Express Shock and Disbelief at Recent Adoption of Poison Pill 30512 311 4 25 Shareholders 26 Former Executive Management of LCA Vision Express Shock and Disbelief at Recent Adoption of Poison Pill 30512 411 4 25 Shareholders 26 Former Executive Management of LCA Vision Express Shock and Disbelief at Recent Adoption of Poison Pill 30512 511 4 25 Shareholders 26 Former Executive Management of LCA Vision Express Shock and Disbelief at Recent Adoption of Poison Pill 30512 611 4 25 Shareholders 26 Former Executive Management of LCA Vision Express Shock and Disbelief at Recent Adoption of Poison Pill 30512 7Thermage Schedules Shareholder Meeting for Vote on the Issuance of Common Stock in Connection With the Reliant Acquisition 30509 1Thermage Schedules Shareholder Meeting for Vote on the Issuance of Common Stock in Connection With the Reliant Acquisition 30509 2Foundation Venture Capital Group Invests in Company Working to Protect Healthy Tissue During Cancer Treatment 30506 1Foundation Venture Capital Group Invests in Company Working to Protect Healthy Tissue During Cancer Treatment 30506 2
...3, 2007 - Affymax, Inc.,(Nasdaq:AFFY) today announ...ical trials of Hematide(TM) in dialysis and,non-di...data showed,that in treatment naive, non-dialysis ...stered monthly at an appropriate dose.,Similarly, ...ith,three-times weekly Epoetin Alfa demonstrated t...
...7 - CytRx Corporation,(NASDAQ:CYTR) today announce...logy exclusively licensed to its majority-owned,su...as been,published in the April 2007 issue of peer-...The technology was developed by RXi,Co-founder, Sc...assachusetts Medical School (UMMS) Professor of Bi...
Other Medicine Technology:Affymax Announces Phase 2 Clinical Trial Results of Once-Per-Month,Hematide for the Treatment of Anemia in Patients with Early- and,End-Stage Chronic Kidney Disease 2Affymax Announces Phase 2 Clinical Trial Results of Once-Per-Month,Hematide for the Treatment of Anemia in Patients with Early- and,End-Stage Chronic Kidney Disease 3CytRx Announces RNAi Delivery Nanoparticle Technology Exclusively,Licensed to Subsidiary, RXi Pharmaceuticals, Described in,Peer-Reviewed Journal 2CytRx Announces RNAi Delivery Nanoparticle Technology Exclusively,Licensed to Subsidiary, RXi Pharmaceuticals, Described in,Peer-Reviewed Journal 3CytRx Announces RNAi Delivery Nanoparticle Technology Exclusively,Licensed to Subsidiary, RXi Pharmaceuticals, Described in,Peer-Reviewed Journal 4
Angled shafts with 4 mm tying patform. Serrated handle with dull finish. Most popular size or model. Overall length 3.2 inches.
Angled 45 degree shafts 8 mm from tip to bend with 4 mm tying platform. Smooth handle with dull finish. Overall length 3.2 inches.
Curved shafts and tips with 6 mm tying platform. Wide serrated handle with dull finish. Overall length 4.3 inches.
Ultra-fine tying platform with round knurled handle for fingertip rotational control. Straight shafts. Overall length 3.9 inches.
Medicine Products: